Rafael Holdings, Inc. (NYSE:RFL) experienced a significant decline in short interest during January 2024. As of January 30, the total short interest stood at 53,017 shares, reflecting a notable decrease of 14.3% from the January 15 total of 61,844 shares. Currently, only 0.2% of the company’s stock is sold short, suggesting a shift in investor sentiment.
Trading data indicates that with an average daily volume of 80,249 shares, the days-to-cover ratio is approximately 0.7 days. This metric highlights the time it would take for short sellers to cover their positions at the current trading volume.
Stock Performance and Market Overview
On January 31, Rafael Holdings’ stock rose by $0.06, reaching $1.25 during midday trading. The trading volume for the day was recorded at 59,235 shares, which is lower than the average volume of 74,577 shares. With a market capitalization of $64.45 million, the company has a price-to-earnings (P/E) ratio of -1.46 and a beta of 0.68, indicating a lower volatility compared to the market.
Over the past year, the stock has fluctuated between a low of $1.12 and a high of $3.19. The fifty-day simple moving average is presently at $1.24, while the 200-day simple moving average is at $1.34.
Analyst Ratings and Institutional Activity
In terms of analyst ratings, Weiss Ratings reaffirmed a “sell (e+)” rating for Rafael Holdings in a report dated December 22, 2023. Currently, one analyst has rated the stock with a sell designation, contributing to an overall average rating of “sell” according to MarketBeat.com.
Institutional trading has seen various hedge funds adjusting their stakes in Rafael. Notably, Simplex Trading LLC established a new position in the second quarter valued at approximately $32,000. Additionally, Marshall Wace LLP acquired shares worth $50,000, while Americana Partners LLC invested $76,000. Citadel Advisors LLC significantly increased its stake by 132.3% in the third quarter, now owning 72,584 shares valued at $99,000 after acquiring an additional 41,335 shares. In total, institutional investors hold 11.30% of the company’s stock.
Rafael Holdings, Inc. is primarily focused on managing interests in clinical and early-stage pharmaceutical companies and commercial real estate assets across the United States and Israel. The company operates through two main segments: Healthcare and Real Estate. Its lead drug candidate, CPI-613 (devimistat), is currently undergoing Phase III clinical trials for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
As Rafael Holdings navigates its market landscape, the recent changes in short interest and trading activity may indicate shifting investor confidence, which will be important to monitor in the coming months.
